Is BPC-157 FDA approved?

BPC-157 is the subject of a favorable FDA advisory committee vote but not FDA approved, and its legal status for compounding is unchanged. It is discussed for research and educational purposes only, not as medical guidance.

Is Teduglutide FDA approved?

Teduglutide is FDA approved (FDA status current as of 2012-12-21). This regulatory status is provided for research and educational context only.

How is BPC-157 administered in research settings?

In research settings, BPC-157 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Teduglutide administered in research settings?

In research settings, Teduglutide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›BPC-157 vs Teduglutide

Peptide Comparison

BPC-157 vs Teduglutide

Name: BPC-157 vs Teduglutide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Tissue Repair peptides.

BPC-157

Body Protection Compound 157

RecoveryAdvisory Vote: FavorableResearch Only

Half-life: Under 30 minutes (plasma); no human PK data

638 providers listed

Full BPC-157 profile →

Teduglutide

Gattex

RecoveryFDA ApprovedPrescription

Half-life: ~2 hours

No providers listed yet

Full Teduglutide profile →

Bottom line

Teduglutide is FDA-approved, while BPC-157 is advisory committee recommended — the clearest structural difference between them.

Quick Verdict

BPC-157

Half-life

Under 30 minutes (plasma); no human PK data

Teduglutide

Half-life

~2 hours

Which One Should You Choose?

Your goal	Better option
Further along in FDA review	Teduglutide
Less frequent dosing (longer half-life)	Teduglutide
Oral administration option	BPC-157
More provider options (638 vs 0)	BPC-157

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

BPC-157

Teduglutide

Mechanism Family

Tissue Repair

Half-life

Under 30 minutes (plasma); no human PK data

~2 hours

FDA Status

advisory committee recommended

approved

Admin Routes

subcutaneous, oral

subcutaneous

Availability

Research Only

Prescription

Providers

638 listed

None listed

FDA Update

Jul 2026

Dec 2012

Avail. Notes

Not FDA-approved for any human use; sold as a research chemical; WADA prohibited (S0). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023. In February 2026 HHS announced an intention to move several peptides toward "Category 1," but the FDA did not reclassify BPC-157. In April 2026 the FDA removed BPC-157 from the Category 2 list because the nomination was withdrawn — this does not authorize compounding, and BPC-157 is not on the 503A bulks list. Provider pricing varies by concentration, formulation, and source; use the PeptideBase directory to compare active providers and current availability.

FDA-approved GLP-2 analog. Brand: Gattex (NDA 203441, Dec 2012). Indicated for short bowel syndrome in adults and paediatric patients. Daily subcutaneous injection. Prescription only.

Research Evidence

BPC-157

Cohort study · 14 key studies · most recent 2026

Teduglutide

Cohort study · 8 key studies · most recent 2026

Research Citations

BPC-157

Cohort2021 · Altern Ther Health Med

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Animal2026 · Pharmaceuticals (Basel)

Unilateral Adrenalectomy, and the Stable Pentadecapeptide BPC 157 as Therapy in Rats-A Cytoprotection Approac…

Animal2026 · Sci Rep

Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury.

In vitro2026 · Int J Mol Sci

BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.

+10 more

Teduglutide

Cohort2026 · Clin Nutr

From childhood to adulthood in chronic intestinal failure: A nationwide study.

Case series2026 · JPGN Rep

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide.

Cohort2026 · Clin Nutr

Growth trajectories of children with short bowel syndrome during the first year of teduglutide treatment.

Cohort2026 · Clin Nutr ESPEN

Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure.

+4 more

About BPC-157

BPC-157 is believed to accelerate angiogenesis and upregulate growth hormone receptors locally at injury sites. It appears to promote fibroblast migration and collagen synthesis, contributing to faster tissue remodelling. Animal studies suggest systemic effects via modulation of the dopaminergic and serotonergic systems, though human data remain limited.

Research Areas

tissue repair across tendon, muscle, nerve, and gut — most broadly studied recovery peptideanti-inflammatory via COX-2 and NF-κB pathway modulationangiogenesis and wound healing via VEGF and nitric oxide system upregulationoral or subcutaneous administration studied — systemic and local tissue effects documented

About Teduglutide

GLP-2 receptor agonist; stimulates intestinal epithelial proliferation and reduces apoptosis; increases intestinal blood flow and inhibits gastric motility

Research Areas

intestinal growthgut repairabsorptive surface restorationshort bowel syndrome treatment

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

BPC-157

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Regulatory Notes

global — WADA

BPC-157 is on the WADA Prohibited List at all times (S0, Non-Approved Substances), effective 1 January 2022. It has no FDA approval and no adequate human clinical trial.

source

Teduglutide

Reported (Unverified — Pending Clinical Review)

GI malignancy or historycolorectal polyps (monitor)

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Used Together?

BPC-157

GHK-Cu
Research suggests GHK-Cu and BPC-157 may produce complementary tissue repair and anti-inflammatory effects when combined. GHK-Cu is studied for copper-dependent collagen synthesis and antioxidant gene activation, while BPC-157 supports angiogenesis and growth factor expression.
TB-500
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Anticoagulants / blood thinners
Research notes that BPC-157 promotes angiogenesis and may influence platelet and vascular function in healing models. Combined use with anticoagulant medications may warrant monitoring. Consult your prescriber before combining.

Price (per mg)

BPC-157

$5.17/mg

$4.36 – $7.30 range

44 vendors

View price index →Find providers →

Teduglutide

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

BPC-157

638 listed

Browse directory →

Providers offering

Teduglutide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Tissue Repair Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). BPC-157 vs Teduglutide — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/bpc-157/teduglutide

https://peptidebase.io/peptides/compare/bpc-157/teduglutide Methodology License Download JSON Download CSV